# VXRT catalysts: Vaxart, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/vxrt/catalysts

> Vaxart, Inc. (VXRT) has 4 upcoming catalysts. The next is the Vaxart, Inc. topline data readout, 1H 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only, quarter only, year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for VXRT?

Vaxart, Inc. (VXRT) has 4 upcoming catalysts. The next is the Vaxart, Inc. topline data readout, 1H 2027. Press release filed with the SEC (EX-99): "The Company expects to release topline efficacy and safety data from the complete study, comprising the 400 participants in the sentinel safety cohort and approximately 5,000 participants in the main cohort, in the first half of 2027." [Calendar and source filings](https://sec-api.dev/companies/vxrt/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001437749-26-026280, https://www.sec.gov/Archives/edgar/data/72444/000143774926026280/ex_1000406.htm (retrieved 2026-11-12). Last confirmed 2026-11-05. Cite: https://sec-api.dev/companies/vxrt/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Vaxart, Inc. |
| Ticker | VXRT (OTC) |
| SEC CIK | 72444 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/vxrt |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Jul 2023 | [Vaxart, Inc. interim data readout](https://sec-api.dev/companies/vxrt/catalysts) | VXRT |  | completed, met | "In July 2023, we announced our Phase 2 placebo-controlled dose-ranging trial evaluating the safety and immunogenicity of our bivalent norovirus vaccine candidate met all primary endpoints and our bivalent norovirus vaccine candidate was well-tolerated with robust immunogenicity based on preliminary topline data." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/72444/000143774924034927/vxrt20240930_10q.htm)) |
| Apr 2024 | [Vaxart, Inc. topline data readout](https://sec-api.dev/companies/vxrt/catalysts) | VXRT |  | completed, positive | "We initiated this study in the fourth quarter of 2023 and announced positive top line results in April 2024." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/72444/000143774926035291/vxrt20260930_10q.htm)) |
| November 13, 2024 | [Vaxart, Inc. earnings report](https://sec-api.dev/companies/vxrt/catalysts) | VXRT |  | completed | "Vaxart Provides Business Update and Reports Third Quarter 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/72444/000143774924034897/ex_716497.htm)) |
| March 20, 2025 | [Vaxart, Inc. earnings report](https://sec-api.dev/companies/vxrt/catalysts) | VXRT |  | completed | "Vaxart Provides Business Update and Reports Full Year 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/72444/000143774925008617/ex_792722.htm)) |
| mid-2025 | [Vaxart, Inc. topline data readout](https://sec-api.dev/companies/vxrt/catalysts) | VXRT |  | scheduled | "The study will measure safety and immune parameters that have correlated to protection in the completed norovirus challenge study, with topline data expected in mid-2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/72444/000143774925016447/ex_817334.htm)) |
| mid-2025 | [Vaxart, Inc. topline data readout](https://sec-api.dev/companies/vxrt/catalysts) | VXRT |  | scheduled | "Completed enrollment of Phase 1 clinical trial evaluating Company's second-generation oral norovirus vaccine constructs, with topline data expected in mid-2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/72444/000143774925016447/ex_817334.htm)) |
| May 13, 2025 | [Vaxart, Inc. earnings report](https://sec-api.dev/companies/vxrt/catalysts) | VXRT |  | completed | "Vaxart Provides Business Update and Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/72444/000143774925016447/ex_817334.htm)) |
| May 27, 2025 | [Vaxart, Inc. trial start](https://sec-api.dev/companies/vxrt/catalysts) | VXRT |  | completed | "SOUTH SAN FRANCISCO, Calif., May 27, 2025 — Vaxart, Inc. (Nasdaq: VXRT) today announced the first patient was dosed in the 10,000-participant portion of its ongoing Phase 2b clinical trial evaluating its oral pill COVID-19 vaccine candidate." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/72444/000143774925018591/ex_824166.htm)) |
| Jun 2025 | [VXA-109 topline data readout](https://sec-api.dev/pdufa/vxa-109) | VXRT |  | completed, positive | "In June 2025, we reported positive topline results from a Phase 1 clinical trial (Study VXA-109) evaluating our second-generation bivalent norovirus vaccine constructs head-to-head against our first-generation bivalent norovirus vaccine constructs." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/72444/000143774926035291/vxrt20260930_10q.htm)) |
| June 11, 2025 | [Vaxart, Inc. topline data readout](https://sec-api.dev/companies/vxrt/catalysts) | VXRT |  | completed, positive | "SOUTH SAN FRANCISCO, Calif., June 11, 2025 — Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today reported positive topline results from the Phase 1 clinical trial evaluating its second-generation oral pill norovirus vaccine constructs head-to-head against its first-generation constructs." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/72444/000143774925020040/ex_829639.htm)) |
| August 13, 2025 | [Vaxart, Inc. earnings report](https://sec-api.dev/companies/vxrt/catalysts) | VXRT |  | completed | "Vaxart Provides Business Update and Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/72444/000143774925026511/ex_852503.htm)) |
| November 13, 2025 | [Vaxart, Inc. earnings report](https://sec-api.dev/companies/vxrt/catalysts) | VXRT |  | completed | "Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/72444/000143774925034829/ex_887249.htm)) |
| March 12, 2026 | [Vaxart, Inc. earnings report](https://sec-api.dev/companies/vxrt/catalysts) | VXRT |  | completed | "Vaxart Provides Business Update and Reports Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/72444/000143774926007968/ex_931491.htm)) |
| Q2 2026 | [Vaxart, Inc. topline data readout](https://sec-api.dev/companies/vxrt/catalysts) | VXRT |  | scheduled | "Topline data from 400-person sentinel cohort of the Phase 2b COVID-19 trial anticipated in Q2 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/72444/000143774926015586/ex_958542.htm)) |
| May 7, 2026 | [Vaxart, Inc. earnings report](https://sec-api.dev/companies/vxrt/catalysts) | VXRT |  | completed | "Vaxart Provides Business Update and Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/72444/000143774926015586/ex_958542.htm)) |
| August 6, 2026 | [Vaxart, Inc. earnings report](https://sec-api.dev/companies/vxrt/catalysts) | VXRT |  | completed | "Vaxart Provides Business Update and Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/72444/000143774926026280/ex_1000406.htm)) |
| Q4 2026 | [Vaxart, Inc. topline data readout](https://sec-api.dev/companies/vxrt/catalysts) | VXRT |  | scheduled | "We are moving quickly toward two critical milestones: the release of 12-month data from our 400-person sentinel cohort expected early in the second quarter, followed by the full readout of comparative efficacy and safety from the main cohort of approximately 5,000 participants in our Phase 2b trial, which we expect in the fourth quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/72444/000143774926007968/ex_931491.htm)) |
| Q4 2026 | [Vaxart, Inc. topline data readout](https://sec-api.dev/companies/vxrt/catalysts) | VXRT |  | scheduled | "Topline data from all participants in the trial are anticipated in the fourth quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/72444/000143774926007968/ex_931491.htm)) |
| November 5, 2026 | [Vaxart, Inc. earnings report](https://sec-api.dev/companies/vxrt/catalysts) | VXRT |  | completed | "Vaxart Provides Business Update and Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/72444/000143774926035275/ex_1039446.htm)) |
| 1H 2027 | [Vaxart, Inc. topline data readout](https://sec-api.dev/companies/vxrt/catalysts) | VXRT |  | scheduled | "The Company expects to release topline efficacy and safety data from the complete study, comprising the 400 participants in the sentinel safety cohort and approximately 5,000 participants in the main cohort, in the first half of 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/72444/000143774926026280/ex_1000406.htm)) |
| 2027 | [Vaxart, Inc. topline data readout](https://sec-api.dev/companies/vxrt/catalysts) | VXRT |  | scheduled | "Topline data from 400-person sentinel safety cohort and approximately 5,000 patients in main cohort Phase 2b COVID-19 trial anticipated by mid-year 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/72444/000143774926035275/ex_1039446.htm)) |
| May 2027 | [Vxa-cov2-3.1 primary completion](https://sec-api.dev/pdufa/vxa-cov2-3-1) | VXRT | SARS-CoV2; COVID-19 | scheduled | "NCT06672055 (A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-05 (ESTIMATED); Lead Sponsor Vaxart." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06672055)) |
| May to Aug 2027 | [Vxa-cov2-3.1 topline data readout](https://sec-api.dev/pdufa/vxa-cov2-3-1) | VXRT | SARS-CoV2; COVID-19 | scheduled | "NCT06672055 (A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-05 (ESTIMATED); Lead Sponsor Vaxart." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06672055)) |

## Drugs

- [VXA-109](https://sec-api.dev/pdufa/vxa-109): 
- [Vxa-cov2-3.1](https://sec-api.dev/pdufa/vxa-cov2-3-1): SARS-CoV2

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/vxrt/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "VXRT catalysts: Vaxart, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/vxrt/catalysts

```bibtex
@misc{secapidev_companies_vxrt_catalysts_20261116,
  title        = {VXRT catalysts: Vaxart, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/vxrt/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_vxrt_catalysts_20261116","title":"VXRT catalysts: Vaxart, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/vxrt/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
